Migraine in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Migraine Major Market Overview

The Migraine market sales across the 7MM was $9.16 billion in 2023. The sales of migraine therapeutics across the 7MM will grow at a compound annual growth rate (CAGR) of more than 5% between 2023 and 2033. The launch of seven new pipeline products will drive growth in the migraine market across the 7MM.

Migraines are primary headaches, wherein the reoccurring headache is not a symptom caused by an underlying disease or condition. However, it is proposed that a complex interaction between genetics and environmental factors plays a large role in causing a migraine attack. The pain is often unilateral and pulsating in nature. It is usually also accompanied by photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

Migraine Market Outlook, 2023-2033 ($ Billion)

Migraine Market Outlook, 2023-2033 ($ Billion)

Buy the Full Report to Know More about the Migraine Market Forecast

Download a Free Report Sample

The Migraine market research report provides a granular forecast growth analysis for both global and regional markets through 2033. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.

Market Size (2023) $9.16 billion
CAGR (2023-2033) >5%
Forecast Period 2023-2033
Key Countries ·       The US

·       France

·       Germany

·       Italy

·       Spain

·       The UK

·       Japan

Key Classes ·       Oral Triptan

·       Nasal Triptan

·       Subcutaneous Triptan

·       Ergot Alkaloid

·       Anti-epileptic

Leading Players ·       GlaxoSmithKline

·       Merck

·       Pfizer

·       Abbvie

·       Novartis

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Migraine Market Segmentation by Countries

A few of the key countries wherein the migraine market is prevalent are the US, France, Germany, Italy, Spain, the UK, and Japan. In 2023, the US accounted for the highest migraine market share in the 7MM, due to the large migraine prevalent population, the high price of branded drugs, and the number of drugs marketed exclusively in the US compared to other countries in the 7MM.

Migraine Market Analysis by Countries, 2023 (%)

Migraine Market Analysis by Countries, 2023 (%)

Buy the Full Report for More Country Insights into the Migraine Market

Download a Free Report Sample

Migraine Market Segmentation by Classes

A few of the migraine classes in the US are oral triptan, nasal triptan, subcutaneous triptan, ergot alkaloid, and anti-epileptic, among others. In 2023, oral triptans accounted for the highest share of the migraine market.

Migraine Market Analysis by Classes, 2023 (%)

Migraine Market Analysis by Classes, 2023 (%)

Buy the Full Report for More Class Insights into the US Migraine Market

Download a Free Report Sample

Migraine Market - Competitive Landscape

A few of the major players in the Migraine market are:

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Abbvie
  • Novartis

Migraine Market Analysis by Players

Migraine Market Analysis by Players

Buy the Full Report to Know More about Companies in the Migraine Market

Download a Free Report Sample

Segments Covered in the Report

Migraine Country Outlook (Value, $ Billion, 2023-2033)

  • The US
  • France
  • Germany
  • Italy
  • Spain
  • The UK
  • Japan

Migraine Class Outlook (Value, $ Billion, 2023-2033)

  • Oral Triptan
  • Nasal Triptan
  • Subcutaneous Triptan
  • Ergot Alkaloid
  • Anti-epileptic

Scope

The report provides:

  • Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM migraine therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM migraine therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

GSK
Dr. Reddy's Laboratories
OptiNose
Currax Pharmaceuticals
Tonix Pharmaceuticals
AstraZeneca
Endo Pharmaceuticals
Almirall
Viatris
Bausch Health Companies
IPI Legacy Liquidation Co
Supernus Pharmaceuticals
Upsher-Smith Laboratories
Sandoz
Merck & Co
Mallinckrodt
AbbVie
Johnson & Johnson
Eli Lilly
Amgen
Teva Pharmaceutical Industries
H. Lundbeck AS
Bristol-Myers Squibb
Axsome Therapeutics
Satsuma Pharmaceuticals
Amneal Pharmaceuticals
Klaria Pharma
Ipsen
Allodynic Therapeutics
Auden McKenzie
Lupin
Orion

Table of Contents

List of Contents

List of Tables

List of Figures

About GlobalData

1 Migraine: Executive Summary

1.1 Migraine therapeutics market will grow to $16.4 billion.

1.2 Key players will maintain their competitive position.

1.3 Environmental unmet needs remain key challenge in migraine market.

1.4 Lack of novelty in late-stage acute pipeline

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification

3.3 Staging

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities.

4.3 Global and historical trends

4.4 7MM forecast methodology.

4.4.1 Sources

4.4.2 Forecast assumptions and methods.

4.4.3 12-month total prevalent cases of migraine

4.4.4 12-month total prevalent cases of migraine by frequency

4.4.5 12-month total prevalent cases of migraine by type

4.4.6 12-month diagnosed prevalent cases of migraine

4.4.7 12-month diagnosed prevalent cases of migraine by frequency

4.4.8 12-month diagnosed prevalent cases of migraine by type

4.5 Epidemiological forecast for migraine (2023–33)

4.5.1 12-month total prevalent cases of migraine

4.5.2 Age-specific 12-month total prevalent cases of migraine

4.5.3 Sex-specific 12-month total prevalent cases of migraine

4.5.4 12-month total prevalent cases of migraine by frequency

4.5.5 12-month total prevalent cases of migraine by type

4.5.6 12-month diagnosed prevalent cases of migraine

4.5.7 Age-specific 12-month diagnosed prevalent cases of migraine.

4.5.8 Sex-specific 12-month diagnosed prevalent cases of migraine.

4.5.9 12-month diagnosed prevalent cases of migraine by frequency

4.5.10 12-month diagnosed prevalent cases of migraine by type

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Access to effective prophylactic treatments

7.3 Treatments for refractory patients`

7.4 Physician education for diagnosis

7.5 Raise awareness of the disease in the general population

8 R&D Strategies

8.1 Overview

8.1.1 Novel MOAs

8.1.2 Combination therapies

8.1.3 Reformulations

8.2 Clinical trials design

8.2.1 Study design

8.2.2 Endpoints

8.2.3 Patient recruitment

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

10.2.1 Acute therapies

10.2.2 Preventive therapies

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

13.7 Contact Us

Frequently asked questions

Migraine in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports
Currency USD
$14,995

Can be used by individual purchaser only

$44,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Migraine in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Migraine reports
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Migraine in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

  • Access a live Migraine in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.